All In Biotech

BLA 761165 · Sandoz INC

Cimerli

Ranibizumab-Eqrn · Injection · Vascular Endothelial Growth Factor Inhibitor

Last checked: Nov 20, 2026Latest source record: May 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Aug 2, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

538

153 Phase 3, 12 recruiting

FAERS reports

162

22 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 7, 2025.

CIMERLI is indicated for the treatment of patients with: CIMERLI, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)

Mechanism: Ranibizumab products bind to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110 . VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO. The binding of ranibizumab products to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • CIMERLI · RANIBIZUMAB-EQRN 0.5MG(10MG/ML) · INJECTABLE, INJECTION · Prescription
  • CIMERLI · RANIBIZUMAB-EQRN 0.3MG(6MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ranibizumab" as an intervention, any sponsor and status, largest first.

All 538 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective62
  • underdose54
  • product administration error13
  • product contamination9
  • product storage error8
  • visual impairment8
  • circumstance or information capable of leading to medication error7
  • death7
  • product use issue6
  • endophthalmitis5
  • product dose omission issue5
  • vision blurred5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202314
202468
202522
202658

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cimerli (Ranibizumab-Eqrn)

2024 spending

$223K

Beneficiaries

40

139 claims

Per beneficiary

$5,579

$24,036.00 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$81,885
2024$223,142

Part B: Cimerli (Ranibizumab-Eqrn) · HCPCS Q5128

2024 spending

$217M

Beneficiaries

38,028

169,956 claims

Per beneficiary

$5,703

2024 ASP limit $230.96 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$122,397,267
2024$216,885,671

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,042 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.